FMP

FMP

Enter

ARAV - Aravive, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ARAV.png

Aravive, Inc.

ARAV

NASDAQ

Inactive Equity

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

0.0401 USD

-0.0062 (-15.46%)

Latest ARAV News

Zacks Investment Research

Oct 13, 2023

Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?

Aravive (ARAV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Read More

Zacks Investment Research

Aug 21, 2023

Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

Aravive (ARAV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.61 per share a year ago.

Read More

InvestorPlace

Aug 3, 2023

Why Is Aravive (ARAV) Stock Down 58% Today?

Aravive (NASDAQ: ARAV ) stock is plummeting on Thursday following the release of results from a Phase 3 clinical trial. The bad news hitting ARAV stock today is that its Phase 3 AXLerate-OC trial did not meet its primary endpoint.

Read More

GlobeNewsWire

Jul 28, 2023

Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature clinical data from the Company's ongoing Phase 1b/2 trials of batiraxcept in clear cell renal cell car...

Read More

InvestorPlace

Jun 15, 2023

3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally

At the heart of every idea for short-squeeze stocks to buy is the ability to make a massive amount of money in a short time period. For a quick recap, those attempting to spark a gamma squeeze essentially take the opposite side of the bearish bet.

Read More

GlobeNewsWire

Jun 5, 2023

Aravive To Participate in the Jefferies Global Healthcare Conference

HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Jefferies Global Healthcare Conference being held on June 7-9, 2023 in New York, NY.

Read More

GlobeNewsWire

May 25, 2023

Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASC...

HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually. The poster presentation will highlight u...

Read More

InvestorPlace

May 18, 2023

7 Short-Interest Stocks to Target for Explosive Gains

Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid market participant also signifies substantial risks.

Read More

Zacks Investment Research

Apr 17, 2023

What Makes Aravive (ARAV) a New Buy Stock

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More

InvestorPlace

Apr 16, 2023

7 Short-Squeeze Stocks That Are Driving Hedge Funds Crazy

Although the concept of gambling on short-squeeze stocks present risks, certain market ideas drive hedge funds crazy. By this statement, I'm referring to companies that speculators believe in their hearts should tumble for various reasons.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep